All In Biotech

Drug Trial Radar · NCT07596901

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Mar 2, 2029

Study completion Mar 2, 2029

Sponsor

Lead sponsor
Aurinia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • AritinerceptDrug

    For subcutaneous injection

  • PlaceboOther

    For subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse eventsTime frame: Baseline to study completion, up to 73 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Aurinia Investigational Site

    Pasadena, California · Recruiting

  • Aurinia Investigational Site

    Altamonte Springs, Florida · Recruiting

  • Aurinia Investigational Site

    Boca Raton, Florida · Recruiting

  • Aurinia Investigational Site

    Homestead, Florida · Recruiting

  • Aurinia Investigational Site

    Miami, Florida · Recruiting

  • Aurinia Investigational Site

    Miami, Florida · Recruiting

  • Aurinia Investigational Site

    Chicago, Illinois · Recruiting

  • Aurinia Investigational Site

    O'Fallon, Illinois · Recruiting

  • Aurinia Investigational Site

    Dearborn, Michigan · Recruiting

  • Aurinia Investigational Site

    Flint, Michigan · Recruiting

  • Aurinia Investigational Site

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.